Longevity Research Pivots to Women as Scientists Study Ovarian Aging
The longevity research field, long dominated by studies on men, is shifting toward women's health. Scientists are now looking at ovarian aging as a key driver of how women age overall, with new therapies targeting ovarian decline rather than just managing menopause symptoms.
Longevity research has historically focused on men. That is starting to change.
The Global Wellness Summit's 2026 trends report identifies women's longevity as one of the year's most significant shifts in health science. Researchers are now studying how women age differently from men, with a particular focus on ovarian decline as a driver of systemic aging.
"Women age fundamentally differently," the report notes. "Ovarian decline significantly accelerates systemic aging." Future interventions, researchers say, will move beyond managing menopause symptoms to addressing ovarian aging itself.
The science is still early. Approaches being studied include ovarian stem cell therapies and treatments targeting ovarian fibrosis. Strength training is also being reframed as a longevity tool for women, not just a fitness activity.
The shift reflects a broader change in how the wellness and medical industries think about women's health. For years, clinical trials enrolled mostly male subjects, leaving gaps in understanding how diseases and treatments affect women differently. Researchers and advocates have pushed for more inclusive study designs, and the results are beginning to show up in the research pipeline.
The longevity market overall is growing fast. Consumers are increasingly interested in extending healthspan, the number of years lived in good health, rather than just lifespan. Biomarkers, wearables, and advanced diagnostics are giving individuals more data about how they are aging.
GLP-1 medications, originally developed for diabetes, are also being studied for their role in longevity and metabolic health. The FDA is expected to approve additional uses for GLP-1 drugs in 2026, and oral formulations are in development.
The Global Wellness Summit report also flagged a backlash against over-optimization, with some consumers stepping back from constant health tracking in favor of more balanced approaches to well-being.
